Northwind Pharmaceuticals

What to Expect from the FDA in 2015

What-to-Expect-from-the-FDA-in-2015The end of the year is coming and 2015 is fast approaching. And as we all start to think about what the New Year will mean for you, what will 2015 hold for pharmaceuticals?

The Federal Drug Administration already has several decisions on the calendar.  According to RTT News,The FDA is so far set to rule on seven proposed medications.

January

  • RYTARY: for the treatment of idiopathic Parkinson’s disease
  • Triferic:  for treating iron deficiency in chronic kidney disease patients on hemodialysis
  • Triferic: for the treatment of iron replacement and maintenance of hemoglobin in hemodialysis patients

February

  • Lucentis: for the treatment of diabetic retinopathy
  • Levosert: a hormonal intrauterine contraceptive for use by women to prevent pregnancy.
  • XIFAXAN: for the treatment of irritable bowel syndrome with diarrhea or IBS-D

March

  • EXPAREL: for use in femoral nerve block for total knee arthroplasty

To read more about the FDA’s 2015 calendar click here.

To stay abreast of all new available medications as well as other points of interest in the constantly-changing world of pharmaceuticals, a reputable partner like Northwind Pharmaceuticals is a great advantage.

Contact us today to see how our solutions can lead to a better 2015.

Schedule a free claims analysis now.

Let’s Talk now

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading

Letter From a Pharmacist – On Pharmacy Closures

Phillip Berry | Oct 25th, 2024
Pharmacists have a time-honored role as an integral contributor to the delivery of health care. From the earliest apothecaries to the retail stores of today, community pharmacists have provided guidance about health, wellness and medication therapy. Their expertise ranges from preventive care to the most advanced medications used in the treatment of complex disease.  Despite … more »

continue reading